Older patients with pulmonary arterial hypertension may have lower pulmonary artery compliance and worse right ventricular performance compared with their younger counterparts.
Balloon pulmonary angioplasty and pulmonary vasodilators were both found to improve functional and hemodynamic outcomes in patients with inoperable chronic thromboembolic pulmonary hypertension.
Left heart disease may be associated with pulmonary hypertension determined by echocardiography.
Significant associations were detected between right heart strain parameters and mean pulmonary arterial pressure and pulmonary capillary wedge pressure in patients with pulmonary hypertension.
Bellerophon Therapeutics announced positive topline data from the phase 2b study of INOpulse® (pulsed, inhaled nitric oxide) delivery system for the treatment of pulmonary hypertension associated with pulmonary fibrosis (PH-PF).
Incorporating preoperative right heart measurements into the standard pulmonary hypertension risk estimation model may allow for better risk stratification following aortic valve replacement.
Pulmonary hypertension can be a severe and potentially debilitating complication in patients with chronic left-sided heart failure.
Systemic anticoagulation was found to improve quality-adjusted life years among patients with idiopathic pulmonary arterial hypertension but not among those with connective tissue disease-associated pulmonary arterial hypertension.
Bellerophon Therapeutics announced positive topline results from cohort 2 of an ongoing phase 2/3 iNO-PF study of INOpulse delivery system for the treatment of PH-ILD.
Cardiac magnetic resonance imaging is useful for risk stratification in patients with pulmonary arterial hypertension.
